DK1499277T3 - PYY-36 til reduktion eller forebyggelse af obesitet - Google Patents
PYY-36 til reduktion eller forebyggelse af obesitetInfo
- Publication number
- DK1499277T3 DK1499277T3 DK02768992T DK02768992T DK1499277T3 DK 1499277 T3 DK1499277 T3 DK 1499277T3 DK 02768992 T DK02768992 T DK 02768992T DK 02768992 T DK02768992 T DK 02768992T DK 1499277 T3 DK1499277 T3 DK 1499277T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyy
- reducing
- preventing obesity
- subject
- decreasing
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 235000019577 caloric intake Nutrition 0.000 abstract 2
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 235000019789 appetite Nutrition 0.000 abstract 1
- 230000036528 appetite Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Liquid Developers In Electrophotography (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fats And Perfumes (AREA)
- Plural Heterocyclic Compounds (AREA)
- Lubricants (AREA)
- Oscillators With Electromechanical Resonators (AREA)
- Lasers (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32440601P | 2001-09-24 | 2001-09-24 | |
| GBGB0200507.2A GB0200507D0 (en) | 2002-01-10 | 2002-01-10 | Appetite suppression |
| US39210902P | 2002-06-28 | 2002-06-28 | |
| PCT/US2002/031944 WO2003026591A2 (en) | 2001-09-24 | 2002-09-24 | Modification of feeding behavior |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1499277T3 true DK1499277T3 (da) | 2009-05-11 |
Family
ID=27256373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02768992T DK1499277T3 (da) | 2001-09-24 | 2002-09-24 | PYY-36 til reduktion eller forebyggelse af obesitet |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7459432B2 (da) |
| EP (2) | EP1499277B1 (da) |
| JP (3) | JP2005508324A (da) |
| KR (1) | KR100989647B1 (da) |
| CN (1) | CN100350968C (da) |
| AT (1) | ATE419863T1 (da) |
| AU (1) | AU2002332054B2 (da) |
| BR (1) | BR0212985A (da) |
| CA (1) | CA2461345A1 (da) |
| DE (1) | DE60230818D1 (da) |
| DK (1) | DK1499277T3 (da) |
| ES (1) | ES2320979T3 (da) |
| HU (1) | HU228621B1 (da) |
| IL (3) | IL160983A0 (da) |
| MX (1) | MXPA04002751A (da) |
| NZ (1) | NZ532427A (da) |
| PL (1) | PL205971B1 (da) |
| WO (1) | WO2003026591A2 (da) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| ES2353728T3 (es) | 1999-02-10 | 2011-03-04 | Curis, Inc. | Péptido yy (pyy) para tratar trastornos metabólicos de la glucosa. |
| US7745216B2 (en) | 1999-02-10 | 2010-06-29 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
| US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
| RU2275207C2 (ru) | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| NZ532427A (en) | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
| US20050015820A1 (en) | 2001-09-24 | 2005-01-20 | Michael Cowley | Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| US7229966B2 (en) * | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
| EA008829B1 (ru) | 2002-12-17 | 2007-08-31 | Нэстек Фармасьютикал Кампани Инк. | Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1594439A2 (en) | 2003-02-13 | 2005-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS |
| ES2425221T3 (es) | 2003-05-30 | 2013-10-14 | Amylin Pharmaceuticals, Llc | Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas |
| EA010160B1 (ru) | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
| EP2417980A1 (en) | 2004-02-11 | 2012-02-15 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
| US8603969B2 (en) * | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| WO2005080424A2 (en) * | 2004-02-23 | 2005-09-01 | Rheoscience A/S | Peptide yy analogues |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| GB0411014D0 (en) * | 2004-05-18 | 2004-06-23 | Haptogen Ltd | Methods for the control treatment and management of obesity |
| US20070213270A1 (en) * | 2004-06-16 | 2007-09-13 | Costantino Henry R | Peptide yy formulations having increased stability and resistance to microbial agents |
| CA2573512C (en) * | 2004-07-12 | 2014-09-23 | Emisphere Technologies, Inc. | Compositions for delivering peptide yy and pyy agonists |
| EP2631244A1 (en) | 2004-10-08 | 2013-08-28 | Amylin Pharmaceuticals, Inc. | Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them |
| CA2589800A1 (en) * | 2004-12-02 | 2006-06-08 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
| EP2360180A3 (en) | 2004-12-13 | 2012-02-08 | Amylin Pharmaceuticals Inc. | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| PA8660701A1 (es) * | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| WO2006086769A2 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
| EP2330124B1 (en) | 2005-08-11 | 2015-02-25 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
| JP2009508885A (ja) | 2005-09-21 | 2009-03-05 | ７ティーエム ファーマ エイ／エス | 治療的介入のためのｙ４選択性レセプターアゴニスト |
| US7851590B2 (en) | 2005-09-21 | 2010-12-14 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
| KR20080048502A (ko) | 2005-09-29 | 2008-06-02 | 머크 앤드 캄파니 인코포레이티드 | 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체 |
| WO2007039318A2 (en) * | 2005-10-06 | 2007-04-12 | Bayer Schering Pharma Aktiengesellschaft | Neuropeptide y analogs |
| AU2006304836A1 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
| US20070232537A1 (en) * | 2005-12-19 | 2007-10-04 | Nastech Pharmaceutical Company Inc. | Intranasal pyy formulations with improved transmucosal pharmacokinetics |
| WO2007085887A1 (en) * | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Pyy agonists and uses thereof |
| MX2008014870A (es) | 2006-05-30 | 2009-02-12 | Intarcia Therapeutics Inc | Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas. |
| US8977517B2 (en) * | 2006-06-05 | 2015-03-10 | Creighton University | System and methods for evaluating efficacy of appetite-affecting drugs |
| GB0613196D0 (en) * | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| MX2009001114A (es) | 2006-08-09 | 2009-02-10 | Intarcia Therapeutics Inc | Sistemas de suministro osmotico y ensambles de piston. |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| CN104000779A (zh) | 2007-04-23 | 2014-08-27 | 精达制药公司 | 促胰岛素释放肽的混悬制剂及其应用 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JP5546451B2 (ja) | 2007-06-04 | 2014-07-09 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト |
| US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
| US7814038B1 (en) * | 2007-12-06 | 2010-10-12 | Dominic John Repici | Feedback-tolerant method and device producing weight-adjustment factors for pre-synaptic neurons in artificial neural networks |
| CA2712606A1 (en) * | 2008-02-08 | 2009-08-13 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010090876A2 (en) | 2009-01-21 | 2010-08-12 | University Of Florida Research Foundation, Inc. | Satiation peptide administration |
| EP2450374B9 (en) * | 2009-07-02 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
| DK2462246T3 (da) | 2009-09-28 | 2017-11-06 | Intarcia Therapeutics Inc | Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse |
| GB201001333D0 (en) | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| RU2600440C3 (ru) | 2010-12-16 | 2021-12-10 | Ново Нордиск А/С | Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты |
| GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| MY159058A (en) | 2011-02-25 | 2016-12-15 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agent |
| KR102007444B1 (ko) | 2011-04-25 | 2019-08-06 | 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 | 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물 |
| US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
| US9456916B2 (en) | 2013-03-12 | 2016-10-04 | Medibotics Llc | Device for selectively reducing absorption of unhealthy food |
| EP2880028B1 (en) | 2012-08-02 | 2020-09-30 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| JP2016516004A (ja) | 2013-02-22 | 2016-06-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病二環式化合物 |
| US9011365B2 (en) | 2013-03-12 | 2015-04-21 | Medibotics Llc | Adjustable gastrointestinal bifurcation (AGB) for reduced absorption of unhealthy food |
| US9067070B2 (en) | 2013-03-12 | 2015-06-30 | Medibotics Llc | Dysgeusia-inducing neurostimulation for modifying consumption of a selected nutrient type |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| HK1220696A1 (zh) | 2013-03-15 | 2017-05-12 | Bausch Health Ireland Limited | 鸟苷酸环化酶激动剂及其用途 |
| EP2983690B1 (en) | 2013-04-10 | 2019-03-27 | University of Copenhagen | Neuropeptide y-derived peptides |
| CA2909045C (en) * | 2013-05-02 | 2022-12-06 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
| AU2014261336B2 (en) | 2013-05-02 | 2019-02-28 | Novo Nordisk A/S | Oral dosing of GLP-1 compounds |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| EP4424697A3 (en) | 2013-06-05 | 2024-12-25 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US9085637B2 (en) | 2013-11-15 | 2015-07-21 | Novo Nordisk A/S | Selective PYY compounds and uses thereof |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| US20170137486A1 (en) | 2014-05-23 | 2017-05-18 | Imperial Innovations Limited | Peptide yy (pyy) analogues |
| BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
| TWI694082B (zh) | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
| KR101604212B1 (ko) * | 2015-07-17 | 2016-03-17 | 울산대학교 산학협력단 | Ｎａｄ를 함유하는 비만 또는 내당능장애의 예방 및 치료용 조성물 |
| JP2019507111A (ja) | 2015-12-22 | 2019-03-14 | ゾゲニクス インターナショナル リミテッド | 代謝抵抗性フェンフルラミン類縁体およびその使用法 |
| KR102688278B1 (ko) | 2015-12-22 | 2024-07-26 | 조게닉스 인터내셔널 리미티드 | 펜플루라민 조성물 및 그 제조 방법 |
| US11311633B2 (en) | 2016-04-16 | 2022-04-26 | University Of Florida Research Foundation, Incorporated | Satiation peptides for weight loss and altered taste sensitivity |
| MA53353A (fr) | 2016-05-16 | 2021-06-09 | Intarcia Therapeutics Inc | Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| CA3032996C (en) | 2016-08-24 | 2025-05-06 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| TWI767945B (zh) | 2016-10-14 | 2022-06-21 | 義大利商Ｔｅｓ製藥（股份）責任有限公司 | α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
| US12240890B2 (en) * | 2017-05-16 | 2025-03-04 | The University Of Chicago | Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| GB201720188D0 (en) | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Analogues of PYY |
| AU2019211322A1 (en) | 2018-01-23 | 2020-07-23 | Gila Therapeutics, Inc. | Peptide YY pharmaceutical formulations, compositions, and methods |
| BR112020014624A2 (pt) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante |
| GB2573145A (en) * | 2018-04-26 | 2019-10-30 | Univ Ulster | Peptides for metabolic disease |
| CA3097335A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| AU2019384963B2 (en) | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| CN113302189B (zh) | 2018-11-20 | 2025-09-05 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| CN113092427A (zh) * | 2021-04-02 | 2021-07-09 | 南京中医药大学 | 异硫氰酸荧光素在标记β内啡肽中的应用 |
Family Cites Families (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4175122A (en) | 1975-04-15 | 1979-11-20 | Burroughs Wellcome Co. | Biologically active amides |
| GB1560933A (en) | 1975-04-15 | 1980-02-13 | Wellcome Found | Biologically activy polypeptides |
| US4223017A (en) | 1975-04-15 | 1980-09-16 | Burroughs Wellcome Co. | Biologically active amides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| US4220653A (en) * | 1979-01-24 | 1980-09-02 | Vivino A Earl | Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight |
| US4229389A (en) | 1979-03-16 | 1980-10-21 | Thompson Marine Corporation | Gas diffuser, aerator, or sparger apparatus |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| DE3374837D1 (en) * | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS607934A (ja) | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造方法 |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US4701441A (en) | 1985-02-11 | 1987-10-20 | University Of Florida | Methods and compositions for stimulation of appetite |
| US4698327A (en) * | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| CA1257199A (en) | 1986-05-20 | 1989-07-11 | Paul Y. Wang | Preparation containing bioactive macromolecular substance for multi-months release in vivo |
| HU196755B (en) | 1986-09-16 | 1989-01-30 | Gyogyszerkutato Intezet | Process for production of new substituated amilid derivatives and medical compositions containing them |
| IE63869B1 (en) | 1986-11-06 | 1995-06-14 | Res Dev Foundation | Aerosols containing liposomes and method for their preparation |
| FI906411A7 (fi) | 1988-06-28 | 1990-12-27 | La Jolla Cancer Res Foundation | Solujen lisääntymisen esto Decorinilla |
| US5026685A (en) | 1988-07-15 | 1991-06-25 | The Salk Institute For Biological Studies | NPY peptide analogs |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| SE9002278L (sv) | 1990-06-28 | 1991-12-29 | Perstorp Ab | Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| JP3419454B2 (ja) | 1991-11-06 | 2003-06-23 | ガーヴァン インスティチュート オブ メディカル リサーチ | ヒト神経ペプチドｙ−ｙ１レセプター |
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| JP3285583B2 (ja) | 1992-10-28 | 2002-05-27 | 株式会社クラレ | ポリウレタン及び該ポリウレタンを使用した皮革様シート |
| JP2961045B2 (ja) * | 1993-02-24 | 1999-10-12 | 日清製粉株式会社 | 腸管粘膜増強促進剤 |
| PL310897A1 (en) | 1993-03-29 | 1996-01-08 | Univ Cincinnati | Analogues of yy peptide and their application |
| WO1995000162A1 (en) | 1993-06-21 | 1995-01-05 | Enzon, Inc. | Site specific synthesis of conjugated peptides |
| GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
| US5965566A (en) | 1993-10-20 | 1999-10-12 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5880131A (en) | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5545549A (en) | 1994-02-03 | 1996-08-13 | Synaptic Pharmaceutical Corporation | DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5696093A (en) | 1994-10-28 | 1997-12-09 | Crc For Biopharmaceutical Research Pty Limited | Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides |
| US6001970A (en) | 1994-11-07 | 1999-12-14 | Merck & Co., Inc | Modified human neuropeptide Y1 Receptors |
| CA2204645A1 (en) * | 1994-11-07 | 1996-05-17 | Keiichi Yano | Novel oxyntomodulin |
| US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
| US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| US5989920A (en) | 1994-12-02 | 1999-11-23 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5 |
| US5907030A (en) | 1995-01-25 | 1999-05-25 | University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| US5912227A (en) * | 1995-01-27 | 1999-06-15 | North Carolina State University | Method of enhancing nutrient uptake |
| US6558708B1 (en) * | 1995-05-17 | 2003-05-06 | Cedars-Sinai Medical Center | Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| US5668151A (en) | 1995-06-07 | 1997-09-16 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
| US5635503A (en) | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Company | Dihydropyridine npy antagonists: piperazine derivatives |
| WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
| PL189289B1 (pl) | 1996-02-02 | 2005-07-29 | Alza Corp | Sposób przygotowania implantowanego układu do dostarczania substancji aktywnej |
| US5962270A (en) | 1996-02-06 | 1999-10-05 | Bionebraska, Inc. | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs |
| US5919901A (en) * | 1996-04-08 | 1999-07-06 | Bayer Corporation | Neuropeptide Y receptor Y5 and nucleic acid sequences |
| US5965392A (en) | 1996-04-08 | 1999-10-12 | Bayer Corporation | Neuropeptide Y receptor Y5 and nucleic acid sequences |
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| AUPO029096A0 (en) | 1996-06-05 | 1996-07-04 | Crc For Biopharmaceutical Research Pty Ltd | Npy y2 agonists |
| US6355478B1 (en) | 1996-06-17 | 2002-03-12 | Eli Lilly And Company | Rhesus monkey neuropeptide Y Y2 receptor |
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| EP0941114B1 (en) | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Use of glp-1 peptides |
| CA2271788A1 (en) | 1996-11-13 | 1998-05-22 | University Of Cincinnati | Analogs of peptide yy and uses thereof |
| EP1629849B2 (en) * | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmaceutical compositions comprising exendins and agonists thereof |
| EP0921817B1 (en) | 1997-01-29 | 2001-03-28 | PolyMASC Pharmaceuticals plc | Pegylation process |
| US6048900A (en) | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
| US6001836A (en) | 1997-05-28 | 1999-12-14 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: cyanoguanidine derivatives |
| US5889016A (en) | 1997-06-26 | 1999-03-30 | Bristol-Myers Squibb Company | Dihydropyrimidone derivatives as NPY antagonists |
| US6093692A (en) | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| EP0920864A1 (en) | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
| US6803357B1 (en) * | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
| FR2774674B1 (fr) | 1998-02-10 | 2000-03-24 | Atochem Elf Sa | Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre |
| DE69942307D1 (de) | 1998-02-27 | 2010-06-10 | Novo Nordisk As | N-terminal veränderte glp-1 abkömmlinge |
| US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
| FR2777283B1 (fr) | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US5993414A (en) | 1998-04-23 | 1999-11-30 | Medtronic, Inc. | Implantable device |
| ES2223170T3 (es) | 1998-04-29 | 2005-02-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aminotetralinas n sustituidas, ligandos del receptor y y5 del neuropeptido que sirve para el tratamiento de la obesidad y otros trastornos. |
| EP1119543B1 (en) | 1998-10-07 | 2004-12-15 | Ortho-McNeil Pharmaceutical, Inc. | N-aralkylaminotetralins as ligands for the neuropeptide y y5 receptor |
| TWI242000B (en) | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
| WO2000042026A1 (en) | 1999-01-15 | 2000-07-20 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| ES2353728T3 (es) * | 1999-02-10 | 2011-03-04 | Curis, Inc. | Péptido yy (pyy) para tratar trastornos metabólicos de la glucosa. |
| US6407120B1 (en) | 1999-02-18 | 2002-06-18 | Pfizer Inc. | Neuropeptide Y antagonists |
| CA2369549A1 (en) | 1999-04-02 | 2000-10-12 | Robert W. Desimone | Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| US6218408B1 (en) | 1999-06-30 | 2001-04-17 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (bicyclics) |
| US6340683B1 (en) | 1999-04-22 | 2002-01-22 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (triazines) |
| HK1041263A1 (zh) | 1999-05-05 | 2002-07-05 | Ortho-Mcneil Pharmaceutical, Inc. | 可用於治疗肥胖和其他疾病的3a，4，5，9b-四氢-1h-苯并[e]吲-2-基胺衍生的神经肽y受体配体 |
| US7601691B2 (en) * | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
| DE60036367T2 (de) | 1999-06-21 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes |
| US6225330B1 (en) | 1999-06-30 | 2001-05-01 | Synaptic Pharmaceutical Corporation | Selective NPY (Y5) antagonists (tricyclics) |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US6399631B1 (en) | 1999-07-23 | 2002-06-04 | Pfizer Inc. | Carbazole neuropeptide Y5 antagonists |
| EP1202986B1 (en) | 1999-07-28 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders |
| EP1207161B1 (en) | 1999-08-25 | 2006-01-18 | Banyu Pharmaceutical Co., Ltd. | Novel isoindole derivatives |
| WO2001014368A1 (en) | 1999-08-26 | 2001-03-01 | Viropharma Incorporated | Compounds, compositions and methods for treating influenza |
| JP2003507424A (ja) | 1999-08-26 | 2003-02-25 | ブリストル−マイヤーズ スクイブ カンパニー | Ｎｐｙアンタゴニスト：スピロイソキノリノン誘導体 |
| AU7738100A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
| AU1269501A (en) | 1999-11-12 | 2001-05-30 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
| US6436091B1 (en) | 1999-11-16 | 2002-08-20 | Microsolutions, Inc. | Methods and implantable devices and systems for long term delivery of a pharmaceutical agent |
| HUP0302969A3 (en) * | 1999-11-26 | 2005-05-30 | Shionogi & Co | Npyy5 antagonists, pharmaceutical compositions containing them and their use |
| DK1246638T4 (da) | 2000-01-10 | 2014-09-22 | Amylin Pharmaceuticals Llc | Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi |
| WO2001066135A1 (en) | 2000-03-08 | 2001-09-13 | Novo Nordisk A/S | Lowering serum lipids |
| AU2001254686A1 (en) | 2000-03-16 | 2001-09-24 | Bayer Aktiengesellschaft | Regulation of human neuropeptide y-like g protein-coupled receptor |
| IL142707A0 (en) * | 2000-04-27 | 2002-03-10 | Pfizer Prod Inc | Methods of treating obesity using a neurotensin receptor ligand |
| US6432960B2 (en) | 2000-05-10 | 2002-08-13 | Bristol-Myers Squibb Company | Squarate derivatives of dihydropyridine NPY antagonists |
| US6444675B2 (en) | 2000-05-10 | 2002-09-03 | Bristol-Myers Squibb Company | 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists |
| EP1286697A2 (en) | 2000-05-17 | 2003-03-05 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| US6256216B1 (en) * | 2000-05-18 | 2001-07-03 | Integrated Device Technology, Inc. | Cam array with minimum cell size |
| WO2001089554A2 (en) | 2000-05-19 | 2001-11-29 | Bionebraska, Inc. | Treatment of acute coronary syndrome with glp-1 |
| US6391881B2 (en) | 2000-05-19 | 2002-05-21 | Bristol-Myers Squibb Company | Thiourea derivatives of dihydropyridine NPY antagonists |
| KR100854851B1 (ko) | 2000-07-06 | 2008-08-27 | 메타베이시스 테라퓨틱스, 인크. | 당뇨병 치료에 유용한 ＦＢＰａｓｅ 억제제와 항당뇨제의조합물 |
| US6420352B1 (en) | 2000-07-19 | 2002-07-16 | W. Roy Knowles | Hair loss prevention |
| US6586403B1 (en) * | 2000-07-20 | 2003-07-01 | Salpep Biotechnology, Inc. | Treating allergic reactions and inflammatory responses with tri-and dipeptides |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| US20020156010A1 (en) * | 2000-11-20 | 2002-10-24 | Lustig Robert H. | Method of treating obesity in adult patients exhibiting primary insulin hypersecretion |
| RU2275207C2 (ru) * | 2000-12-14 | 2006-04-27 | Амилин Фармасьютикалз, Инк. | Способ снижения доступности питательного вещества, способ подавления аппетита |
| WO2002066479A1 (en) | 2001-02-23 | 2002-08-29 | Banyu Pharmaceutical Co.,Ltd. | Novel isoindole derivatives |
| WO2002067918A1 (en) | 2001-02-27 | 2002-09-06 | Banyu Pharmaceutical Co., Ltd. | Novel diallylmethylamine derivative |
| IL159643A0 (en) * | 2001-07-26 | 2004-06-01 | Schering Corp | Substituted urea neuropeptide y y5 receptor antagonists |
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| NZ532427A (en) | 2001-09-24 | 2008-07-31 | Imp Innovations Ltd | Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y) |
| CA2472882A1 (en) | 2002-01-10 | 2003-07-17 | Imperial College Innovations Ltd | Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour |
| US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| CA2521784C (en) * | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| CN1220702C (zh) | 2003-07-30 | 2005-09-28 | 北京中科亚光生物科技有限公司 | 促胰岛素分泌肽及其用途 |
| WO2005035761A1 (en) | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
| KR20120133403A (ko) | 2004-06-01 | 2012-12-10 | 도만티스 리미티드 | 증강된 혈청 반감기를 가지는 이특이성 융합 항체 |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| WO2006134340A2 (en) | 2005-06-13 | 2006-12-21 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| WO2007056362A2 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| AU2007221366B2 (en) | 2006-02-22 | 2012-08-23 | Msd Italia S.R.L. | Oxyntomodulin derivatives |
| EP2046367A4 (en) | 2006-06-07 | 2009-11-11 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
-
2002
- 2002-09-24 NZ NZ532427A patent/NZ532427A/en not_active IP Right Cessation
- 2002-09-24 AT AT02768992T patent/ATE419863T1/de not_active IP Right Cessation
- 2002-09-24 HU HU0600337A patent/HU228621B1/hu not_active IP Right Cessation
- 2002-09-24 JP JP2003530230A patent/JP2005508324A/ja active Pending
- 2002-09-24 EP EP02768992A patent/EP1499277B1/en not_active Expired - Lifetime
- 2002-09-24 EP EP20080022583 patent/EP2050460A1/en not_active Withdrawn
- 2002-09-24 US US10/490,776 patent/US7459432B2/en not_active Expired - Fee Related
- 2002-09-24 CN CNB028185846A patent/CN100350968C/zh not_active Expired - Fee Related
- 2002-09-24 PL PL374270A patent/PL205971B1/pl not_active IP Right Cessation
- 2002-09-24 IL IL16098302A patent/IL160983A0/xx unknown
- 2002-09-24 AU AU2002332054A patent/AU2002332054B2/en not_active Ceased
- 2002-09-24 CA CA002461345A patent/CA2461345A1/en not_active Abandoned
- 2002-09-24 BR BR0212985-0A patent/BR0212985A/pt not_active Application Discontinuation
- 2002-09-24 KR KR1020097023184A patent/KR100989647B1/ko not_active Expired - Fee Related
- 2002-09-24 DE DE60230818T patent/DE60230818D1/de not_active Expired - Lifetime
- 2002-09-24 ES ES02768992T patent/ES2320979T3/es not_active Expired - Lifetime
- 2002-09-24 MX MXPA04002751A patent/MXPA04002751A/es active IP Right Grant
- 2002-09-24 DK DK02768992T patent/DK1499277T3/da active
- 2002-09-24 WO PCT/US2002/031944 patent/WO2003026591A2/en not_active Ceased
-
2004
- 2004-03-21 IL IL160983A patent/IL160983A/en not_active IP Right Cessation
-
2008
- 2008-08-29 US US12/202,197 patent/US8217001B2/en not_active Expired - Fee Related
-
2009
- 2009-06-15 IL IL199364A patent/IL199364A/en not_active IP Right Cessation
-
2010
- 2010-01-08 JP JP2010003242A patent/JP2010111694A/ja active Pending
-
2012
- 2012-11-29 JP JP2012260485A patent/JP6124565B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1499277T3 (da) | PYY-36 til reduktion eller forebyggelse af obesitet | |
| WO2003057235A3 (en) | Modification of feeding behavior | |
| ZA200410153B (en) | Improved combine vaccine against mycoplasma hyopneumoniae and porcine viruses | |
| DK1377280T3 (da) | Fyldmidler som mæthedsfornemmelsesgivende midler | |
| NL1024447A1 (nl) | Werkwijzen en inrichtingen voor afknottingscompensatie. | |
| NO20035526D0 (no) | Forbindelser for behandling av metabolske forstyrrelser | |
| DK2251419T3 (da) | Porcint reproduktions- og respirations-syndrom-vaccine baseret på isolat JA-142 | |
| AU2003266658A1 (en) | Text edition device and program | |
| DE50212520D1 (de) | Turbokompressor mit verstellbaren Leitschaufeln | |
| IL176758A0 (en) | 1,3-dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | |
| AU2003252182A8 (en) | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | |
| AU2003218462A1 (en) | Treatment of obesity and other disorders associated with excessive food intake | |
| EP1495039A4 (en) | MUTANTS OF NEISSERIA, LIPOOLIGOSACCHARIDES AND IMMUNOGENIC COMPOSITIONS | |
| ATE341297T1 (de) | Orthopädische schiene | |
| IL182976A0 (en) | Mutant porcine reproductive and respiratory syndrome virus | |
| ITRM20030485A0 (it) | Composizione a base di citicolina in associazione con vitamine per laprevenzione ed il trattamento di patolgie oculari. | |
| ITMI20030786A1 (it) | Dispositivo di guida e di serraggio. | |
| FI6078U1 (fi) | Tukikaide | |
| NO20052752D0 (no) | Oromukosalpreparat og fremgangsmate for fremstilling derav. | |
| HK1097834A (en) | 1 , 3 - dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | |
| AU2003217466A8 (en) | Facl4 and mutation thereof on x-linkend mental retardation syndrome | |
| SE0203563D0 (sv) | Natrumedel med smärtlindrande egenskap | |
| NO20030825D0 (no) | Anordning og fremgangsmåte for innstilling av kurvatur på ryggdelene for stol | |
| ITRM20020023U1 (it) | Manopola personalizzata per motocicli e motociclette. | |
| ES1051976Y (es) | Pieza ceramica perfeccionada. |